General description
“Cytokine” is a general term used for a diverse group of soluble proteins and peptides which act as regulators under both normal and pathological conditions to modulate the functional activities of individual cells and tissues. These proteins also mediate direct interactions between cells and regulate processes taking place in the extracellular environment. The cytokine group of proteins includes lymphokines, interferons, colony stimulating factors and chemokines. Cytokine and chemokine research plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, as well as disease states such as inflammatory disease, allergic reactions, irritable bowel disease (IBD), sepsis, and cancer.
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 20 analytes in human serum, plasma, and cell culture supernatants.
Analytes included: BAFF/Blys, BRAK/CXCL14, CCL28, CXCL16, HCC-4/CCL16, HMGB1, IFNβ, IL-14, IL-19, IL-24, IL-28B, IL-32α, IL-34, IL-35, IL-36β/IL-1F8, IL-37/IL-1F7, IL-38/IL-1F10, MIP-4, MPIF/CCL23, YKL40
Note: HMGB1 can be measured in serum and plasma samples only.
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
Emerging Biomarker Coverage: Quantify 20 understudied targets like IL-37 (anti-inflammatory), YKL-40 (fibrosis marker), and HMGB1 (DAMP molecule), unlocking insights into novel immune-regulatory pathways and disease mechanisms.
Precision Dilution Protocols: Optimized 1:4 dilution for serum/plasma balances sensitivity and matrix interference, while tissue culture compatibility supports in vitro model validation.
Modular Assay Design: Curate analyte subsets (e.g., CCL28 for mucosal immunity, IL-28B for viral response) to align with niche hypotheses, maximizing resource efficiency.
Dual Incubation Flexibility: Choose overnight (16–18 hr) for low-abundance targets (e.g., IL-34) or fast 2-hour workflows for high-concentration analytes.
Niche Pathway Profiling: Targets include IL-36β (psoriasis), BRAK/CXCL14 (tumor suppression), and IL-35 (autoimmunity), bridging gaps in inflammation and oncology research.
Legal Information
Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
For research use only. Not for use in diagnostic procedures.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
